Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
about
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysisDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsA Review of Management of Inflammation in the HIV PopulationMoving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialDifferential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray studyPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Abnormal cardiac strain in children and young adults with HIV acquired in early life.Impact of the Data Collection on Adverse Events of Anti-HIV Drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada.Do HIV-infected non-small cell lung cancer patients receive guidance-concordant care?Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV diseaseEffects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era.Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic reviewClinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Cardiovascular disease in HIV patients: from bench to bedside and backwards.Epidemiology and management of antiretroviral-associated cardiovascular disease.Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.Factors related to NT-proBNP levels in HIV patients aged over 40 years.Relaxation effect of abacavir on rat basilar arteries.Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclaseEndothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic miceIs there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort studyLamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population.Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veteransRacial Disparities in Creatinine-based Kidney Function Estimates Among HIV-infected Adults.Pathophysiology and management of cardiovascular disease in patients with HIVAssociation of tenofovir exposure with kidney disease risk in HIV infection.Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature.Antiviral efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV-infected children and adolescents: a systematic review protocol.Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Epidemiology of ischemic heart disease in HIV.
P2860
Q21999480-727DA13B-7714-40D1-8A49-097E511D036CQ26768591-365FA3FB-4A5C-4F3A-8496-88BC9FC2FD0FQ28078962-30EB3AA0-2204-4A5F-806A-6C132D5CABDCQ28540037-52C2145B-4390-4D41-9D45-313BFC466255Q28543075-17E62D54-B55D-4BFD-80D9-72338F443F3FQ28741214-956E835B-4FB0-451B-830F-431120B9046AQ30248286-F5701C43-3204-47A7-9413-D1811491C81AQ30452923-F3981D88-FE39-4E82-B557-09D9D06F10C9Q30657374-FB570FEC-8547-4E51-96E1-705CC316FE01Q33719504-7C9FC814-654B-450B-AE80-35E091555111Q34077477-8C359847-9E30-4BEE-9BA0-0739FF9950D2Q34157856-FA67CDFF-46D9-4373-82E9-2812F8F179C9Q34301401-C55DF068-CB7A-48DC-8AC8-1AE3BBF31255Q34555483-F33A7EB1-4F7C-47BA-BE81-6AF305E64623Q34651525-428D6CCE-F1A1-447A-91FF-51C7071380ABQ34736194-B2AA3D80-8C11-48B5-A46E-E09003CAF265Q35203971-B6E9CC5C-52D3-4D53-8F5D-4329374B1C34Q35338096-13A06429-9AE5-4DC6-AF7C-9F2945A1E815Q35542679-8465BA39-0CD6-466A-9CC3-E42BB46206A1Q35589294-7386CD3E-5318-4C89-B35A-79FD7F761E00Q35597616-0C38ABCB-4A86-4CFE-BF21-C9DF4B664FF3Q35737682-0A063D7C-DAD8-4D83-A57C-17950E1B09D1Q35804762-B6670F7C-ACC6-487F-B02C-03B42A895995Q35977313-6D6A7D3C-6F5F-4B2F-8BC5-E0AA8DDDA0EEQ36098224-4EE33FD4-8DB3-49AA-8127-0A4B86551EF3Q36311127-69C7D0C1-0068-498A-8A5B-F848D51CE361Q36338387-85B99C37-2041-49C7-A681-17260BB2F6F7Q36578046-81123550-F864-4367-8C36-42306FBA4054Q36693929-4F46B833-D5A1-4D3F-BADB-2FCB0C635766Q36746411-2182AB60-84DE-430C-93F7-6161381BFE48Q36813322-D209EA33-F47D-4856-9082-07CB3F78BB24Q37038775-AC89A679-C312-48EE-B965-C4E923CE9964Q37077982-4D64B3A3-6C31-449E-AC31-297FA52A88FDQ37993138-5000EA32-19DE-4546-B4B2-409EA085CA21Q38021848-BB62602F-E6EB-4216-8DB2-B2C68441FE70Q38170576-A594C790-74B9-4AAA-AE2F-E3EF0525D86FQ38239183-88DA6599-E476-49F4-BE4D-540F3C8724F2Q38591208-42A0F128-32C2-4447-AFEC-64B5473D68CCQ38596011-1BB9175E-22C1-4971-B46B-4E91B3614A61Q38629009-94FE6376-2C2F-47E3-BAAD-A87104052B8C
P2860
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular risks associate ...... osure in HIV-infected persons.
@en
Cardiovascular risks associate ...... osure in HIV-infected persons.
@nl
type
label
Cardiovascular risks associate ...... osure in HIV-infected persons.
@en
Cardiovascular risks associate ...... osure in HIV-infected persons.
@nl
prefLabel
Cardiovascular risks associate ...... osure in HIV-infected persons.
@en
Cardiovascular risks associate ...... osure in HIV-infected persons.
@nl
P2093
P2860
P1433
P1476
Cardiovascular risks associate ...... osure in HIV-infected persons.
@en
P2093
Andy I Choi
Cristin C Weekley
Eric Vittinghoff
Yongmei Li
P2860
P304
P356
10.1097/QAD.0B013E328347FA16
P407
P577
2011-06-01T00:00:00Z